About Arcion Therapeutics
Arcion Therapeutics applies breakthroughs in neuroscience to advance the treatment of chronic pain. The company focuses on topical treatments to provide pain relief with convenient application and reduced systemic side effects. Arcion's core technology is based on research which showed that in many neuropathic pain conditions, the signal that triggers pain actually arises at the level of the skin. This finding provides a strong biological rationale for developing topically delivered drugs to target the pain at the source - the pain receptors in the skin. Arcion's product pipeline comprises multiple candidates to treat neuropathic pain. ARC-4558 is a topical 0.1% clonidine gel being developed for the treatment of painful diabetic neuropathy (PDN). It is a clear, water-based, fast-drying gel that provides pain relief that rivals approved oral drugs. ARC-4558 has a minimal side-effect profile with low/undetectable systemic levels of clonidine with over 600 patients treated in clinical trials to date.
Missing: Arcion Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Arcion Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Arcion Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Arcion Therapeutics is included in 2 Expert Collections, including Diabetes.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Arcion Therapeutics Patents
Arcion Therapeutics has filed 4 patents.
Anticonvulsants, Analgesics, Amines, Antidepressants, Peripheral nervous system disorders
Anticonvulsants, Analgesics, Amines, Antidepressants, Peripheral nervous system disorders
Latest Arcion Therapeutics News
Jun 16, 2017
Anesiva files for bankruptcy after Arcion merger falls through This article was originally published in Scrip 05 Jan 2010 Executive Summary Anesiva is to file for bankruptcy protection after its proposed merger with Arcion Therapeutics, which appeared to be the struggling pharmaceutical company's saviour in August, was terminated. Already Registered? Sign in to continue reading. Your login and/or password information does not match our records. Please try again. Forgot your password? Forgot your password? Enter the email address associated with your account and an email will be sent to you to reset your password. Please enter a valid email address. Unfortunately we've not been able to process this request. Submit Phone (UK & Europe): +44 (20) 337 73737 Phone (APAC): +61 2 8705 6907 New to Scrip? Request a free trial today! Your username does not meet the requirements. An account with that username already exists. Unfortunately we've not been able to process your registration. Please contact support. Register Your login and/or password information does not match our records. Please try again. Forgot your password? Forgot your password? Enter the email address associated with your account and an email will be sent to you to reset your password. Please enter a valid email address. Unfortunately we've not been able to process this request. Submit Phone (UK & Europe): +44 (20) 337 73737 Phone (APAC): +61 2 8705 6907 Authentication.SignIn.HeadSignInHeader Forgot your password? Forgot your password? Enter the email address associated with your account and an email will be sent to you to reset your password. Please enter a valid email address. Unfortunately we've not been able to process this request. Submit Phone (UK & Europe): +44 (20) 337 73737 Phone (APAC): +61 2 8705 6907 UsernamePublicRestriction Sorry - this email domain is not allowed. Sorry - public email accounts are not allowed. Please provide a work email address. An account with that username already exists. Unfortunately we've not been able to process your registration. Please contact support. Register All fields are required. Please make sure you have filled out all fields Please make sure you have filled out all fields Please enter a valid e-mail address Please enter a valid Phone Number Ask your question to our analysts Cancel All fields are required. For multiple recipients, separate email addresses with a semicolon. Please make sure all fields are completed. Please enter a valid e-mail address Please make sure you have filled out all fields Please make sure you have filled out all fields Subject: Anesiva files for bankruptcy after Arcion merger falls through Add a personalized message to your email Cancel Send Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe. Sign In To Set a Search Alert Your login and/or password information does not match our records. Please try again. Forgot your password?
Arcion Therapeutics Frequently Asked Questions (FAQ)
Where is Arcion Therapeutics's headquarters?
Arcion Therapeutics's headquarters is located at 2400 Boston Street, Baltimore.
What is Arcion Therapeutics's latest funding round?
Arcion Therapeutics's latest funding round is Debt - IV.
How much did Arcion Therapeutics raise?
Arcion Therapeutics raised a total of $17M.
Who are the investors of Arcion Therapeutics?
Investors of Arcion Therapeutics include InterWest Partners, Presidio Partners and Emerging Technology Center.
Who are Arcion Therapeutics's competitors?
Competitors of Arcion Therapeutics include Affibody, Lipella Pharmaceuticals, Elusys Therapeutics, Threshold Pharmaceuticals, Pique Therapeutics and 14 more.
Compare Arcion Therapeutics to Competitors
Chroma Therapeutics is a biotechnology company founded to exploit the potential of chromatin biology for cancer drug discovery. Chroma is focused on the identification of anti-cancer agents that combine the efficacy of cytotoxics with the tumour cell selectivity of modern targeted therapeutics. Based in Oxford, UK, Chroma is developing a pipeline of anti-cancer drugs.
BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.
Anaborex Anaborex is an early stage biotechnology company developing drugs for the treatment of the wasting syndrome many cancer patients experience towards the late stages of their disease.
ARC Pharmaceuticals Inc. is a privately owned biotechnology company developing medical products for the treatment of proliferative diseases. The Company holds exclusive intellectual property related to the treatment of surgical adhesions, rheumatoid arthritis, osteoarthritis and psoriasis. ARC's initial focus is on the prevention of surgical adhesion disease, a major complication in a high proportion of common surgical procedures causing pain and dysfunction in millions of patients worldwide.
Avestha Gengraine Technologies is a biotechnology & bioinformatics company, focusing on the convergence between food, pharmaceuticals and clinical genomics leading to preventive personalized medicine. . Avesthagen was founded by Dr. Villoo Morawala-Patell in 1998, on the premise that the time was ripe for India to establish its own research and discovery based biotechnology industry. Avesthagen aims to provide solutions for global challenges in agriculture & health problems in the areas of degenerative conditions, metabolic disorders and infectious diseases.
Traxion Therapeutics Inc. is a biotech company focused on the development of drugs for the treatment of intractable pain, specifically neuropathic pain. Traxion has assembled a portfolio of small molecule products to address this market opportunity. These products use more selective, mechanism-based approaches which exploit recent scientific discoveries in order to develop what Traxion believes are more effective, better tolerated treatments for neuropathic pain.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.